Does Ibrance (palbociclib) cause side effects?
Ibrance (palbociclib) is a kinase inhibitor used to treat adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or in combination with fulvestrant in patients with disease progression following endocrine therapy.
Common side effects of Ibrance include
- anemia,
- weakness,
- fatigue,
- anemia,
- upper respiratory infection,
- nausea,
- inflammation of the mouth and lips,
- mouth sores,
- hair thinning or loss,
- diarrhea,
- low blood platelets,
- decreased appetite,
- vomiting,
- numbness or tingling in extremities,
- nosebleed,
- blurred vision,
- dry or watery eyes,
- headache,
- changes in taste,
- constipation,
- rash,
- dry skin, and
- fever.
Serious side effects of Ibrance include
- low white blood cell count (neutropenia),
- interstitial lung disease, and
- pneumonitis.
Drug interactions of Ibrance include
- azole antifungals,
- antiviral medications,
- macrolide antibiotics,
- nefazodone,
- verapamil,
- grapefruit or grapefruit juice,
- antiseizure medications,
- rifampin,
- St John's wort,
- bosentan,
- modafinil,
- nafcillin,
- midazolam,
- alfentanil,
- cyclosporine,
- dihydroergotamine,
- ergotamine,
- everolimus,
- fentanyl,
- pimozide,
- quinidine,
- sirolimus, and
- tacrolimus.
Ibrance can cause fetal harm when administered to a pregnant woman. Females of reproductive potential are advised to use effective contraception during treatment with Ibrance and for at least 3 weeks after the last dose.
There is no information regarding the presence of Ibrance in breast milk, its effects on milk production, or the breastfed infant. Because of the potential for serious adverse reactions in breastfed infants from Ibrance, breastfeeding women are advised not to breastfeed during treatment with Ibrance and for 3 weeks after the last dose.
What are the important side effects of Ibrance (palbociclib)?
Neutropenia
- Neutropenia was the most frequently reported adverse reaction in Study 1 (PALOMA-2) with an incidence of 80% and Study 2 (PALOMA-3) with an incidence of 83%.
- A Grade ≥3 decrease in neutrophil counts was reported in 66% of patients receiving Ibrance plus letrozole in Study 1 and 66% of patients receiving Ibrance plus fulvestrant in Study 2.
- In Study 1 and 2, the median time to first episode of any grade neutropenia was 15 days and the median duration of Grade ≥3 neutropenia was 7 days.
- Monitor complete blood counts prior to starting Ibrance therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated.
- Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.
- Febrile neutropenia has been reported in 1.8% of patients exposed to Ibrance across Studies 1 and 2.
- One death due to neutropenic sepsis was observed in Study 2. Physicians should inform patients to promptly report any episodes of fever.
Embryo-Fetal Toxicity
- Based on findings from animal studies and its mechanism of action, Ibrance can cause fetal harm when administered to a pregnant woman.
- In animal reproduction studies, administration of palbociclib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity at maternal exposures that were ≥4 times the human clinical exposure based on area under the curve (AUC).
- Advise pregnant women of the potential risk to a fetus.
- Advise females of reproductive potential to use effective contraception during treatment with Ibrance and for at least 3 weeks after the last dose.
Ibrance (palbociclib) side effects list for healthcare professionals
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Neutropenia
- ILD/Pneumonitis
Clinical Studies Experience
Because clinical trials are conducted under varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.
Study 1: Ibrance Plus Letrozole
Patients With Estrogen Receptor (ER)-positive, HER2-negative Advanced Or Metastatic Breast Cancer For Initial Endocrine Based Therapy
The safety of Ibrance (125 mg/day) plus letrozole (2.5 mg/day) versus placebo plus letrozole was evaluated in Study 1 (PALOMA-2).
The data described below reflect exposure to Ibrance in 444 out of 666 patients with ER-positive, HER2-negative advanced breast cancer who received at least 1 dose of Ibrance plus letrozole in Study 1.
The median duration of treatment for Ibrance plus letrozole was 19.8 months while the median duration of treatment for placebo plus letrozole arm was 13.8 months.
Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving Ibrance plus letrozole. No dose reduction was allowed for letrozole in Study 1.
Permanent discontinuation associated with an adverse reaction occurred in 43 of 444 (9.7%) patients receiving Ibrance plus letrozole and in 13 of 222 (5.9%) patients receiving placebo plus letrozole. Adverse reactions leading to permanent discontinuation for patients receiving Ibrance plus letrozole included neutropenia (1.1%) and alanine aminotransferase increase (0.7%).
The most common adverse reactions (≥10%) of any grade reported in patients in the Ibrance plus letrozole arm by descending frequency were
- neutropenia,
- infections,
- leukopenia,
- fatigue,
- nausea,
- alopecia,
- stomatitis,
- diarrhea,
- anemia,
- rash,
- asthenia,
- thrombocytopenia,
- vomiting,
- decreased appetite,
- dry skin,
- pyrexia, and
- dysgeusia.
The most frequently reported Grade >3 adverse reactions (≥5%) in patients receiving Ibrance plus letrozole by descending frequency were
- neutropenia,
- leukopenia,
- infections, and
- anemia.
Adverse reactions (≥10%) reported in patients who received Ibrance plus letrozole or placebo plus letrozole in Study 1 are listed in Table 4.
Table 4: Adverse Reactions (≥10%) in Study 1
Adverse Reaction | Ibrance plus Letrozole (N=444) | Placebo plus Letrozole (N=222) | ||||
All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % | |
Infections and infestations | ||||||
Infectionsa | 60b | 6 | 1 | 42 | 3 | 0 |
Blood and lymphatic system disorders | ||||||
Neutropenia | 80 | 56 | 10 | 6 | 1 | 1 |
Leukopenia | 39 | 24 | 1 | 2 | 0 | 0 |
Anemia | 24 | 5 | <1 | 9 | 2 | 0 |
Thrombocytopenia | 16 | 1 | <1 | 1 | 0 | 0 |
Metabolism and nutrition disorders | ||||||
Decreased appetite | 15 | 1 | 0 | 9 | 0 | 0 |
Nervous system disorders | ||||||
Dysgeusia | 10 | 0 | 0 | 5 | 0 | 0 |
Gastrointestinal disorders | ||||||
Stomatitisc | 30 | 1 | 0 | 14 | 0 | 0 |
Nausea | 35 | <1 | 0 | 26 | 2 | 0 |
Diarrhea | 26 | 1 | 0 | 19 | 1 | 0 |
Vomiting | 16 | 1 | 0 | 17 | 1 | 0 |
Skin and subcutaneous tissue disorders | ||||||
Alopecia | 3d | N/A | N/A | 16e | N/A | N/A |
Rashf | 18 | 1 | 0 | 12 | 1 | 0 |
Dry skin | 12 | 0 | 0 | 6 | 0 | 0 |
General disorders and administration site conditions | ||||||
Fatigue | 37 | 2 | 0 | 28 | 1 | 0 |
Asthenia | 17 | 2 | 0 | 12 | 0 | 0 |
Pyrexia | 12 | 0 | 0 | 9 | 0 | 0 |
Grading according to CTCAE 4.0. CTCAE=Common Terminology Criteria for Adverse Events; N=number of patients; N/A=not applicable; a Infections includes all reported preferred terms (PTs) that are part of the System Organ Class Infections and infestations. b Most common infections (≥1%) include: nasopharyngitis, upper respiratory tract infection, urinary tract infection, oral herpes, sinusitis, rhinitis, bronchitis, influenza, pneumonia, gastroenteritis, conjunctivitis, herpes zoster, pharyngitis, cellulitis, cystitis, lower respiratory tract infection, tooth infection, gingivitis, skin infection, gastroenteritis viral, respiratory tract infection, respiratory tract infection viral, and folliculitis. c Stomatitis includes: aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oral discomfort, oropharyngeal pain, and stomatitis. d Grade 1 events - 30%; Grade 2 events - 3%. e Grade 1 events - 15%; Grade 2 events - 1%. f Rash includes the following PTs: rash, rash maculo-papular, rash pruritic, rash erythematous, rash papular, dermatitis, dermatitis acneiform, and toxic skin eruption. |
Additional adverse reactions occurring at an overall incidence of <10.0% of patients receiving Ibrance plus letrozole in Study 1 included
- alanine aminotransferase increased (9.9%),
- aspartate aminotransferase increased (9.7%),
- epistaxis (9.2%),
- lacrimation increased (5.6%),
- dry eye (4.1%),
- vision blurred (3.6%), and
- febrile neutropenia (2.5%).
Table 5: Laboratory Abnormalities in Study 1
Laboratory Abnormality | Ibrance plus Letrozole (N=444) | Placebo plus Letrozole (N=222) | ||||
All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % | |
WBC decreased | 97 | 35 | 1 | 25 | 1 | 0 |
Neutrophils decreased | 95 | 56 | 12 | 20 | 1 | 1 |
Anemia | 78 | 6 | 0 | 42 | 2 | 0 |
Platelets decreased | 63 | 1 | 1 | 14 | 0 | 0 |
Aspartate aminotransferase increased | 52 | 3 | 0 | 34 | 1 | 0 |
Alanine aminotransferase increased | 43 | 2 | <1 | 30 | 0 | 0 |
N=number of patients; WBC=white blood cells. |
Study 2: Ibrance Plus Fulvestrant
Patients with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Have Had Disease Progression On Or After Prior Adjuvant Or Metastatic Endocrine Therapy
The safety of Ibrance (125 mg/day) plus fulvestrant (500 mg) versus placebo plus fulvestrant was evaluated in Study 2 (PALOMA-3). The data described below reflect exposure to Ibrance in 345 out of 517 patients with HR-positive, HER2-negative advanced or metastatic breast cancer who received at least 1 dose of Ibrance plus fulvestrant in Study 2. The median duration of treatment for Ibrance plus fulvestrant was 10.8 months while the median duration of treatment for placebo plus fulvestrant arm was 4.8 months.
Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving Ibrance plus fulvestrant. No dose reduction was allowed for fulvestrant in Study 2.
Permanent discontinuation associated with an adverse reaction occurred in 19 of 345 (6%) patients receiving Ibrance plus fulvestrant, and in 6 of 172 (3%) patients receiving placebo plus fulvestrant. Adverse reactions leading to discontinuation for those patients receiving Ibrance plus fulvestrant included
- fatigue (0.6%),
- infections (0.6%), and
- thrombocytopenia (0.6%).
The most common adverse reactions (≥10%) of any grade reported in patients in the Ibrance plus fulvestrant arm by descending frequency were
- neutropenia,
- leukopenia,
- infections,
- fatigue,
- nausea,
- anemia,
- stomatitis,
- diarrhea,
- thrombocytopenia,
- vomiting,
- alopecia,
- rash,
- decreased appetite, and
- pyrexia.
The most frequently reported Grade ≥3 adverse reactions (≥5%) in patients receiving Ibrance plus fulvestrant in descending frequency were neutropenia and leukopenia.
Adverse reactions (≥10%) reported in patients who received Ibrance plus fulvestrant or placebo plus fulvestrant in Study 2 are listed in Table 6.
Table 6: Adverse Reactions (≥10%) in Study 2
Adverse Reaction | Ibrance plus Fulvestrant (N=345) | Placebo plus Fulvestrant (N=172) | ||||
All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % | |
Infections and infestations | ||||||
Infectionsa | 47b | 3 | 1 | 31 | 3 | 0 |
Blood and lymphatic system disorders | ||||||
Neutropenia | 83 | 55 | 11 | 4 | 1 | 0 |
Leukopenia | 53 | 30 | 1 | 5 | 1 | 1 |
Anemia | 30 | 4 | 0 | 13 | 2 | 0 |
Thrombocytopenia | 23 | 2 | 1 | 0 | 0 | 0 |
Metabolism and nutrition disorders | ||||||
Decreased appetite | 16 | 1 | 0 | 8 | 1 | 0 |
Gastrointestinal disorders | ||||||
Nausea | 34 | 0 | 0 | 28 | 1 | 0 |
Stomatitisc | 28 | 1 | 0 | 13 | 0 | 0 |
Diarrhea | 24 | 0 | 0 | 19 | 1 | 0 |
Vomiting | 19 | 1 | 0 | 15 | 1 | 0 |
Skin and subcutaneous tissue disorders | ||||||
Alopecia | 18d | N/A | N/A | 6e | N/A | N/A |
Rashf | 17 | 1 | 0 | 6 | 0 | 0 |
General disorders and administration site conditions | ||||||
Fatigue | 41 | 2 | 0 | 29 | 1 | 0 |
Pyrexia | 13 | <1 | 0 | 5 | 0 | 0 |
Grading according to CTCAE 4.0. CTCAE=Common Terminology Criteria for Adverse Events; N=number of patients; N/A=not applicable. a Infections includes all reported preferred terms (PTs) that are part of the System Organ Class Infections and infestations. b Most common infections (≥1%) include: nasopharyngitis, upper respiratory infection, urinary tract infection, bronchitis, rhinitis, influenza, conjunctivitis, sinusitis, pneumonia, cystitis, oral herpes, respiratory tract infection, gastroenteritis, tooth infection, pharyngitis, eye infection, herpes simplex, and paronychia. c Stomatitis includes: aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort, oropharyngeal pain, stomatitis. d Grade 1 events - 17%; Grade 2 events - 1%. e Grade 1 events - 6%. f Rash includes: rash, rash maculo-papular, rash pruritic, rash erythematous, rash papular, dermatitis, dermatitis acneiform, toxic skin eruption. |
Additional adverse reactions occurring at an overall incidence of <10.0% of patients receiving Ibrance plus fulvestrant in Study 2 included
- asthenia (7.5%),
- aspartate aminotransferase increased (7.5%),
- dysgeusia (6.7%),
- epistaxis (6.7%),
- lacrimation increased (6.4%),
- dry skin (6.1%),
- alanine aminotransferase increased (5.8%),
- vision blurred (5.8%),
- dry eye (3.8%), and
- febrile neutropenia (0.9%).
Table 7: Laboratory Abnormalities in Study 2
Laboratory Abnormality | Ibrance plus Fulvestrant (N=345) | Placebo plus Fulvestrant (N=172) | ||||
All Grades % | Grade 3 % | Grade 4 % | All Grades % | Grade 3 % | Grade 4 % | |
WBC decreased | 99 | 45 | 1 | 26 | 0 | 1 |
Neutrophils decreased | 96 | 56 | 11 | 14 | 0 | 1 |
Anemia | 78 | 3 | 0 | 40 | 2 | 0 |
Platelets decreased | 62 | 2 | 1 | 10 | 0 | 0 |
Aspartate aminotransferase increased | 43 | 4 | 0 | 48 | 4 | 0 |
Alanine aminotransferase increased | 36 | 2 | 0 | 34 | 0 | 0 |
N=number of patients; WBC=white blood cells. |
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Ibrance. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Respiratory Disorders: Interstitial lung disease (ILD)/non-infectious pneumonitis.
Male Patients With HR-Positive, HER2-Negative Advanced Or Metastatic Breast Cancer
Based on limited data from postmarketing reports and electronic health records, the safety profile for men treated with Ibrance is consistent with the safety profile in women treated with Ibrance.
What drugs interact with Ibrance (palbociclib)?
- Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A.
Agents That May Increase Palbociclib Plasma Concentrations
Effect Of CYP3A Inhibitors
- Coadministration of a strong CYP3A inhibitor (itraconazole) increased the plasma exposure of palbociclib in healthy subjects by 87%.
- Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole).
- Avoid grapefruit or grapefruit juice during Ibrance treatment.
- If coadministration of Ibrance with a strong CYP3A inhibitor cannot be avoided, reduce the dose of Ibrance.
Agents That May Decrease Palbociclib Plasma Concentrations
Effect Of CYP3A Inducers
- Coadministration of a strong CYP3A inducer (rifampin) decreased the plasma exposure of palbociclib in healthy subjects by 85%.
- Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wort).
Drugs That May Have Their Plasma Concentrations Altered By Palbociclib
- Coadministration of midazolam with multiple doses of Ibrance increased the midazolam plasma exposure by 61%, in healthy subjects, compared to administration of midazolam alone.
- The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced, as Ibrance may increase its exposure.
Summary
Ibrance (palbociclib) is a kinase inhibitor used to treat adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or in combination with fulvestrant in patients with disease progression following endocrine therapy. Common side effects of Ibrance include anemia, weakness, fatigue, anemia, upper respiratory infection, nausea, inflammation of the mouth and lips, mouth sores, hair thinning or loss, diarrhea, low blood platelets, decreased appetite, vomiting, numbness or tingling in extremities, nosebleed, blurred vision, dry or watery eyes, headache, changes in taste, constipation, rash, dry skin, and fever. Females of reproductive potential are advised to use effective contraception during treatment with Ibrance and for at least 3 weeks after the last dose. There is no information regarding the presence of Ibrance in breast milk, its effects on milk production, or the breastfed infant.
Multimedia: Slideshows, Images & Quizzes
-
Breast Cancer Awareness: Symptoms, Diagnosis, and Treatment
Learn about breast cancer causes, symptoms, tests, recovery, and prevention. Discover the types of treatments such as surgery and...
-
10 Things Young Women Should Know About Breast Cancer
Is breast cancer genetic? Should I get tested for the BRCA gene? What every young women should know about breast cancer. Discover...
-
Breast Cancer Quiz: Symptoms & Signs
This Breast Cancer Quiz features signs, symptoms, facts, causes, common forms, terms, risk factors, statistics, and more. ...
-
Breast Cancer: Where It Can Spread
When breast cancer spreads, or metastasizes, it often goes to these five places: the lymph nodes, bones, liver, lungs, and brain....
Related Disease Conditions
-
Breast Cancer in Men
Second Source WebMD Medical Reference
-
How Common Is Lymphovascular Invasion in Breast Cancer?
About 30% of breast cancers metastasize to nearby blood vessels and lymph nodes, a process called lymphovascular invasion.
-
Male Breast Cancer
Male breast cancer accounts for 1% of all breast cancers, and most cases are found in men between the ages of 60 and 70. A man's risk of developing breast cancer is one in 1,000. Signs and symptoms include a firm mass located below the nipple and skin changes around the nipple, including puckering, redness or scaling, retraction and ulceration of the nipple. Treatment depends upon staging and the health of the patient.
-
Triple-Negative Breast Cancer
Triple-negative breast cancer is more common in Hispanic and African-American women. Signs and symptoms include a lump in the armpit or breast, nipple discharge and inversion, and changes in the breast's skin. Treatment may incorporate surgery, chemotherapy, and radiation therapy.
-
Breast Cancer
Breast cancer is an invasive tumor that develops in the mammary gland. Breast cancer is detected via mammograms, breast self-examination (BSE), biopsy, and specialized testing on breast cancer tissue. Treatment of breast cancer may involve surgery, radiation, hormone therapy, chemotherapy, and targeted therapy. Breast cancer risk may be lowered by managing controllable risk factors. What you should know about breast cancer Breast cancer is the most common cancer among American women. One in every eight women in the United States develops breast cancer. There are many types of breast cancer that differ in their capability of spreading (metastasize) to other body tissues. The causes of breast cancer are unknown, although medical professionals have identified a number of risk factors. There are 11 common types of breast cancer and 4 uncommon types of breast cancer. Breast cancer early signs and symptoms include a lump in the breast or armpit, bloody nipple discharge, inverted nipple, orange-peel texture or dimpling of the breast's skin (peau d'orange), breast pain or sore nipple, swollen lymph nodes in the neck or armpit, and a change in the size or shape of the breast or nipple. Breast cancer can also be symptom free, which makes following national screening recommendations an important practice. Breast cancer is diagnosed during a physical exam, by a self-exam of the breasts, mammography, ultrasound testing, and biopsy. Treatment of breast cancer depends on the type of cancer and its stage (0-IV) and may involve surgery, radiation, or chemotherapy.
-
Can Fibroadenomas Turn Into Breast Cancer?
A fibroadenoma is the most common type of benign, non-cancerous lump of the breast. Although it is rare, complex fibroadenomas and phyllodes tumors have a chance to develop into malignant breast cancer.
-
Inflammatory Breast Cancer
Inflammatory breast cancer is an accelerated form of breast cancer that is not usually detected by mammogram or ultrasound. Symptoms of inflammatory breast cancer include pain in the breast, skin change in the breast area, bruise on the breast,sudden swelling of the breast, nipple retraction or discharge, and swelling of the lymph nodes.
-
Breast Cancer Prevention
Lifestyle changes, a healthy antioxidant-rich diet, exercise, and weight reduction can help reduce a woman's risk of developing breast cancer. It's important to be aware of how risk factors such as family history, lifestyle factors, breast conditions, radiation therapy, and hormonal factors may influence your chances of developing breast cancer. Mammography and breast self-examinations are crucial steps in breast cancer prevention.
-
Breast Cancer and Lymphedema
Lymphedema is a common chronic, debilitating condition in which excess fluid called lymph collects in tissues and causes swelling in them. It is common after a mastectomy, lumpectomy or breast cancer surgery and radiation therapy.
-
Breast Cancer and Coping With Stress
Being diagnosed with breast cancer is stressful. Learning relaxation techniques, exercising, eating well, getting adequate sleep, receiving psychotherapy, and maintaining a positive attitude can help you cope. Creating documents, such as an advance directive, living will, and durable power of attorney will outline your wishes in the event that you are no longer able to make decisions regarding your care.
-
Breast Cancer Recurrence
Breast cancer most often recurs within the first 3-5 years after the initial treatment. Changes in the look, feel, or appearance of the breast may indicate breast cancer recurrence. Factors related to recurrence include tumor size, tumor grade, hormone receptor status, lymph node involvement, and oncogene expression. Check out the center below for more medical references on breast cancer, including multimedia (slideshows, images, and quizzes), related diseases, treatment, diagnosis, medications, and prevention or wellness.
-
Breast Cancer Early Warning Signs and Symptoms
In most cases, there are no early warning signs of breast cancer. Breast cancer may not produce any early symptoms, and in many cases, it is first discovered on screening mammography. The most common sign of breast cancer is a new lump or mass in the breast.
-
What Is Usually the First Sign of Breast Cancer?
A lump in the breast or in the armpits is often the first sign of breast cancer. This may be felt while in the shower. There may or may not be changes in the structure of the breast. Other early signs include changes in breast skin, breast pain and others.
-
Breast Cancer Stages
Breast cancer staging is the determination of the extent and spread of cancer. An individual's health care team uses stages to summarize the extent of cancer in a standardized way that is recognized by all health care providers. They use this staging to determine the treatment most appropriate for the type of cancer. Cancer staging helps to determine the prognosis, or outlook, of cancer, including rates of recurrence and survival rates.
-
What Should I Know About Breast Cancer?
Breast cancer is the most common non-skin cancer of American women, but it can also occur in men. Every year in the U.S., there are over 266,000 new diagnoses of breast cancer. A woman has a risk of one in eight for developing breast cancer at some point during her lifetime.
-
HER2-Positive Breast Cancer
In about 10%-20% of breast cancers, the cancer cells test positive for HER2, sometimes referred to as the HER2/neu protein. HER2 is a growth-promoting protein located on the surface of some cancer cells. HER2-positive breast cancers tend to grow more rapidly and spread more aggressively than breast cancers that are HER2-negative. Doctors do not know what specifically causes some breast cancers to express this protein while others do not.
-
Breast Cancer Treatment by Stage
Treatment of breast cancer depends upon the stage of the cancer at the time of diagnosis. Some of the various treatments include: hormone therapy, radiation therapy, surgery, chemotherapy, HER2-targeted therapy, neoadjuvant therapy, and adjuvant therapy.
-
Breast Cancer Treatment
Breast cancer treatments depend upon the type of breast cancer that is present as well as the stage (extent of spread) of the tumor. Treatment for early breast cancer typically involves surgery to remove the tumor. After surgery, medical professionals may administer radiation therapy, chemotherapy, or targeted therapy.
-
What Is the Breast Cancer BRCA Gene Test?
BRCA genes (BRCA 1 and 2, when normal, repair damaged DNA) are among the genetic mutations linked to breast cancer, ovarian cancer, and other cancers when mutated. Every woman with a BRCA mutation is at high risk for breast cancer, irrespective of whether she has a family history of breast cancer or not. By age 80, a woman with a BRCA mutation has about an 80% chance of developing breast cancer. BRCA1 and BRCA2 gene mutations also increase the risk of ovarian cancer, by 54% and 23%, respectively.
-
What Questions Should I Ask My Doctor About Breast Cancer?
A diagnosis of breast cancer can be overwhelming, so it's important to write down all your questions before meeting with your doctor.
-
What Are the Four Types of Breast Cancer?
The four most common types of breast cancer are ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal carcinoma, invasive lobular carcinoma. The designations are based on the locations of the tumors, whether they have spread and where they have spread to.
-
What Are The Five Warning Signs Of Breast Cancer?
The majority of breast cancer patients first seek diagnosis because of a lump on the breast. This is one of the five warning signs of breast cancer. Others include changes in the nipple, changes in the breast skin and other symptoms.
-
Breast Cancer During Pregnancy
Breast cancer occurs in about 1 in every 1,000 pregnant women. Treatment of breast cancer during pregnancy involves surgery, but it is very difficult to protect the baby from the dangerous effects of radiation and chemotherapy. It can be an agonizing to decide whether or not to undergo breast cancer treatment while one is pregnant.
-
Breast Cancer in Young Women
About 5% of cases of breast cancer occur in women under the age of 40 years old. Some risk factors for breast cancer in young women include a personal history of breast cancer or breast disease, family history of breast cancer, prior radiation therapy, and the presence of BRCA1/BRCA2 gene mutations. Breast self-exams, clinical breast exams, and screening mammograms may help detect breast cancer. Treatment may include surgery, chemotherapy, radiation, and hormone therapy.
-
Breast Cancer Growth Rate
The available evidence suggests that breast cancer may begin to grow around 10 years before it is detected. However, the time for development differs from tumor to tumor.
-
Breast Cancer Clinical Trials
Breast cancer clinical trials are research programs designed to evaluate new medical treatments, drugs, or devices for the treatment of breast cancer. Clinical trials are designed to test the safety and efficacy of new treatments as well as assess potential side effects. Clinical trials also compare new treatment to existing treatments to determine if it's any better. There are many important questions to ask your doctor before taking part in a breast cancer clinical trial.
-
How Can You Detect Breast Cancer Early?
Breast cancer develops from the cells of the breasts and can spread to other parts of the body (metastasis). It is one of the most common cancers diagnosed in women in the United States. A lump in the breast or armpit is often the first sign. Treatment success depends largely on early detection.
-
Genetic Testing: Families With Breast Cancer
Breast cancer can be a killer and the decision to get tested to see if a patient is prone to the disease should be discussed with a doctor -- particularly if the woman has a history of breast cancer in her family. Genetic testing can only tell so much about breast cancer risk, however.
Treatment & Diagnosis
- Breast Cancer
- Breast Cancer Husband
- Breast Cancer: A Feisty Women's Discussion
- Inflammatory Breast Cancer
- Breast Cancer
- Breast Cancer: Mother-daughter relationships
- Breast Cancer, Taking Control: Self-Advocacy 101
- Breast Cancer: The Male View on Survival and Support
- Breast Cancer: Early Diagnosis and Prevention
- Breast Cancer Treatments. Oct. 29, 2002.
- Breast Cancer: Early Stage Treatments
- Breast Cancer: Clinical Trials - Today's Cutting Edge
- Breast Cancer, Metastatic: Treatment Goals and Therapy Options -- Harold J. Burstein, MD
- Breast Cancer Treatment Update
- Breast Cancer FAQs
- Breast Cancer Risk - Reduced With Exercise
- Herceptin Metastatic Breast Cancer Treatment
- Breastfeeding -- Protection from Breast Cancer?
- Hormone Therapy in Survivors of Breast Cancer
- Breast Cancer: Types of Breast Cancer
- Elizabeth Edwards has Breast Cancer Alert
- Stress and Aggressive Breast Cancer: Cause or Effect?
- Advanced Breast Cancer in Young Women Increasing
- Angelina Jolie's Mastectomy
- Exercise Improves Breast Cancer Survival
- Does Positive Additude Affect Breast Cancer?
- How Common and Dangerous Is Male Breast Cancer?
- How Many Breast Cancer Deaths Are there Each Year?
- Where Can Breast Cancer Spread To?
- Why Is Breast Cancer More Common in Females than Males?
- How Much Breast Cancer is Genetic?
- How Long Can Breast Cancer Patients Live?
- Who Does Breast Cancer Affect?
- How Does Breast Cancer Form?
- How Many Breast Cancer Stages Are There?
- Facts on Breast Cancer Causes, Risk Factors, and Types
- Breast Cancer Symptoms and Signs
- Breast Cancer Detection
- Breast Cancer Treatment
Medications & Supplements

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.